Verrica Pharmaceuticals (VRCA) Change in Receivables (2023 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Change in Receivables of $2.5 million for Q1 2026, down 55.68% year-over-year from $5.6 million in Q1 2025, and up 237.88% quarter-over-quarter from -$1.8 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Change in Receivables (2023 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Change in Receivables history runs 4 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 55.68% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.1 million (up 251.87% YoY), while the FY2025 annual figure was $5.2 million, up 224.1% from the prior year.
- Change in Receivables for Q1 2026 stood at $2.5 million, up from -$1.8 million in the prior quarter.
- The five-year high for Change in Receivables was $5.6 million in Q1 2025, with the low at -$10.2 million in Q3 2024.
- The 4-year median for Change in Receivables is $2.5 million (2026), against an average of $666909.1.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables soared 333.72% in 2024, then slumped 989.05% in 2025.
- Verrica Pharmaceuticals' Change in Receivables stood at -$86000.0 in 2023, then surged by 333.72% to $201000.0 in 2024, then plunged by 989.05% to -$1.8 million in 2025, then jumped by 237.88% to $2.5 million in 2026.
- Business Quant data shows VRCA's Change in Receivables at $2.5 million in Q1 2026, -$1.8 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 2.46 Mn |
| Mar 31, 2026 | 2.46 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Dec 31, 2025 | -1.79 Mn |
| Sep 30, 2025 | -2.15 Mn |
| Sep 30, 2025 | -2.15 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 201,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | -10.18 Mn |
| Sep 30, 2024 | -10.18 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Mar 31, 2024 | 2.75 Mn |